An Imaging Agent (Perflutren Lipid Microspheres) With Ultrasound for Imaging of Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-05-26
Target enrollment:
Participant gender:
Summary
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be
used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is
an ultrasound contrast agent that is typically used for ultrasound bubble studies that
involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles.
These microbubbles are about the size of a red blood cell and do not stay in a patient's body
for more than several minutes, where they are excreted from the lungs and exhaled back into
the air when breathing. Definity may enhance ultrasound images of the prostate and help
doctors identify prostate cancer on ultrasound images.